Hengrui Pharma(SH:600276) 智通财经网·2025-09-23 10:08Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, aimed at treating chronic spontaneous urticaria (CSU) patients [1] Group 1: Clinical Development - The clinical trial approval notification for HRS-3095 tablets will allow the company to initiate clinical trials shortly [1] - HRS-3095 is a small molecule compound targeting immune cells, developed independently by the company, showing promising therapeutic effects for allergic diseases [1] Group 2: Preclinical Data - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1] Group 3: Investment and R&D - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]